Colorado has secured federal authorization to import lower-cost prescription drugs from Canada, a move state officials estimate could save residents approximately $46 million on 20 common medications over three years. However, the program faces significant logistical hurdles, including Canadian export restrictions and private manufacturing contracts that currently prevent the sale of these drugs to the United States, according to the Colorado Department of Health Care Policy and Financing.
How does the state plan to source imported medications?
The Colorado Department of Health Care Policy and Financing is currently in discussions with 10 major pharmaceutical manufacturers to secure supply chains, according to department spokesman Marc Williams. The list of manufacturers includes Pfizer, Merck, Novo Nordisk, Johnson & Johnson, and Gilead. The state’s program aims to import high-demand treatments such as the weight-loss medication Ozempic, the blood thinner Eliquis, and the cystic fibrosis drug Trikafta. State projections indicate potential discounts ranging from 18% to 68% compared to current U.S. retail prices.
The U.S. Food and Drug Administration (FDA) is responsible for ensuring that any imported medications meet safety and quality standards. Before reaching a patient, all drugs brought into Colorado under this program must undergo rigorous quality testing.
What are the primary barriers to implementation?
Success depends on overcoming two major regulatory and legal obstacles. First, the Canadian government maintains strict rules to prevent drug shortages, prohibiting manufacturers from exporting medications if such sales would threaten the domestic supply, as reported by Politico. Second, most major pharmaceutical companies utilize private distribution contracts that explicitly restrict their Canadian factories from selling to the American market. While Governor Jared Polis has described the FDA approval as a “vital first step,” these contractual and international trade barriers remain unresolved.
How does Colorado’s program compare to Florida’s?
Colorado’s initiative follows a similar path taken by Florida, which received federal authorization for its own drug importation program in January 2024. As of mid-2026, Florida has yet to successfully import a single unit of medicine for its residents, according to data from the National Association of Boards of Pharmacy. Critics of these state-led efforts, such as the Partnership for Safe Medicines, argue that the programs are ineffective. Executive director Shabbir Imber Safdar stated that Florida has spent $132 million on its program without achieving lower costs, suggesting that Colorado’s approach could similarly result in a drain on state funds without providing financial relief to patients.
Patients should always verify the legitimacy of their pharmacy. Buying drugs from online sources that claim to be “from Canada” carries a significant risk of encountering counterfeit medication if the vendor is not properly licensed or vetted by state health authorities.
Frequently Asked Questions
Will all pharmacies participate in the program?
Not necessarily. According to the Department of Health Care Policy and Financing, the state will establish a participation process for pharmacies once a reliable supply chain is secured. Patients will need to confirm if their specific pharmacy is part of the program and if their health insurance covers the imported versions of their prescriptions.
Are imported drugs safe?
The FDA requires that all medications imported through state-sanctioned programs undergo quality testing to ensure they meet U.S. safety standards. However, the Partnership for Safe Medicines warns that the complexity of these supply chains presents inherent risks that do not exist with domestically regulated products.
What happens if manufacturers refuse to sell to the state?
Without voluntary cooperation from manufacturers, the state faces significant challenges in sourcing the drugs. Currently, Colorado is working to encourage these companies to allow sales, but there is no federal mandate forcing private pharmaceutical firms to supply state-run importation programs.
Stay informed on the latest developments in healthcare policy. Sign up for our weekly newsletter to receive updates directly in your inbox.
